Shandong Sinobioway Biomedicine Co., Ltd. (SHE:002581)

SHE:002581 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Cash & Equivalents	208.57	220.25	506.4	151.91	183.8	187.8
Trading Asset Securities	-	0.02	-	-	-	-
Cash & Short-Term Investments	208.57	220.27	506.4	151.91	183.8	187.8
Cash Growth	-35.88%	-56.50%	233.35%	-17.35%	-2.13%	-33.91%
Accounts Receivable	237.86	279.66	93.32	172.62	179.72	272.96
Other Receivables	10.06	12.07	52.24	78.87	18.36	13.49
Receivables	247.92	291.74	145.55	251.49	198.09	286.45
Inventory	133.4	93.25	79.64	85.31	80.04	64.33
Other Current Assets	26.3	24.08	15.41	7.99	56.43	29.88
Total Current Assets	616.19	629.34	747.01	496.71	518.36	568.45
Property, Plant & Equipment	343.11	349.95	274.74	357.84	705.47	713.76
Long-Term Investments	795.72	938.34	1,056	1,355	1,503	1,223
Other Intangible Assets	85.43	90.81	93.47	108.29	126.32	134.29
Long-Term Deferred Tax Assets	29.6	27.32	11.21	6.12	11.84	25.28
Long-Term Deferred Charges	40.11	9.73	0.32	1.41	5.2	7.78
Other Long-Term Assets	129.49	122.88	13.44	12.26	0.49	83.36
Total Assets	2,040	2,168	2,196	2,337	2,870	2,756

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Accounts Payable	97.69	88.39	35.35	73.69	43.64	42.13
Accrued Expenses	5.7	39.24	20.83	22.5	19.32	31.01
Short-Term Debt	40.5	32.53	2.77	13.84	150.42	151.54
Current Portion of Long-Term Debt	-	16.88	-	-	-	-
Current Portion of Leases	-	0.83	0.17	-	13.46	15.83
Current Income Taxes Payable	1.96	0.25	-	0.95	1.2	0.44
Current Unearned Revenue	2.76	2.99	10.46	3.59	26.86	3.43
Other Current Liabilities	14.46	9.66	13.03	19.03	109.38	14.17
Total Current Liabilities	163.07	190.78	82.61	133.61	364.28	258.54
Long-Term Debt	18.4	8.5	-	-	-	-
Long-Term Leases	3.03	2.69	-	0.71	1.47	9.8
Long-Term Unearned Revenue	5.49	5.49	5.49	5.49	6.71	9.74
Long-Term Deferred Tax Liabilities	9.9	9.59	9.39	7.51	7.68	8.68
Other Long-Term Liabilities	4.91	4.94	76.12	16.09	9.67	-
Total Liabilities	204.8	222	173.61	163.41	389.82	286.76

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Common Stock	229.15	229.15	229.15	229.15	229.15	229.15
Additional Paid-In Capital	942.41	901.28	866.41	873.93	858.5	858.29
Retained Earnings	575.16	711.79	828.08	965.39	1,298	1,301
Total Common Equity	1,747	1,842	1,924	2,068	2,385	2,388
Minority Interest	88.14	104.16	98.67	105.26	94.94	81.11
Shareholders' Equity	1,835	1,946	2,022	2,174	2,480	2,469
Total Liabilities & Equity	2,040	2,168	2,196	2,337	2,870	2,756

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022
Total Debt	61.93	61.43	2.94	14.55	165.35	177.16
Net Cash (Debt)	146.64	158.84	503.47	137.36	18.45	10.64
Net Cash Growth	-42.37%	-68.45%	266.52%	644.38%	73.50%	-90.91%
Net Cash Per Share	0.22	0.24	0.76	0.21	0.03	0.02
Filing Date Shares Outstanding	659.77	659.74	659.74	659.74	659.74	659.74
Total Common Shares Outstanding	659.77	659.74	659.74	659.74	659.74	659.74
Working Capital	453.11	438.56	664.4	363.1	154.08	309.91
Book Value Per Share	2.65	2.79	2.92	3.14	3.62	3.62
Tangible Book Value	1,661	1,751	1,830	1,960	2,259	2,254
Tangible Book Value Per Share	2.52	2.65	2.77	2.97	3.42	3.42
Buildings	-	440.69	393.55	486.08	639.62	612.92
Machinery	-	423.85	431.4	432.25	413.16	424.47
Construction In Progress	-	104.46	38.11	22.17	91.43	64.86

Data Source: S&P Global Market Intelligence Last updated: Oct 22, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 24, 2026

Data Sources Report a data error